An  	An  	 DT	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
safety  	safety  	 NN	O
data  	data  	 NNS	O
from  	from  	 IN	O
five  	five  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
on  	on  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
botulinum  	botulinum  	 JJ	B-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A-ABO  	A-ABO  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
A  	A  	 DT	O
new  	new  	 JJ	O
formulation  	formulation  	 NN	B-NP
of  	of  	 IN	I-NP
a  	a  	 DT	I-NP
botulinum  	botulinum  	 JJ	I-NP
neurotoxin  	neurotoxin  	 JJ	I-NP
type  	type  	 NN	I-NP
A  	A  	 DT	O
( 	( 	 -LRB-	O
BoNTA-ABO 	BoNTA-ABO 	 NNP	B-NP
;  	;  	 :	O
Dysport  	Dysport  	 NNP	B-NP
[ 	[ 	 -LRB-	O
abobotulinumtoxinA 	abobotulinumtoxinA 	 NNP	B-NP
] 	] 	 -RRB-	O
;  	;  	 :	O
Medicis  	Medicis  	 NNP	B-NP
Aesthetics 	Aesthetics 	 NNP	I-NP
,  	,  	 ,	O
Scottsdale 	Scottsdale 	 NNP	B-NP
,  	,  	 ,	O
AZ 	AZ 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
recently  	recently  	 RB	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	O
and  	and  	 CC	O
Drug  	Drug  	 NNP	B-NP
Administration  	Administration  	 NNP	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
article  	article  	 NN	O
summarizes  	summarizes  	 VBD	O
the  	the  	 DT	O
safety  	safety  	 NN	O
data  	data  	 NNS	O
from  	from  	 IN	O
five  	five  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
investigating  	investigating  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
.  	.  	 .	O
Of  	Of  	 IN	O
the  	the  	 DT	O
five  	five  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
studies  	studies  	 NNS	O
conducted 	conducted 	 VBN	O
,  	,  	 ,	O
three  	three  	 CD	O
were  	were  	 VBD	O
multicenter 	multicenter 	 CD	B-NP
,  	,  	 ,	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
placebo-controlled 	placebo-controlled 	 NNP	O
,  	,  	 ,	O
double-blind  	double-blind  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
and  	and  	 CC	O
two  	two  	 CD	O
were  	were  	 VBD	O
multicenter 	multicenter 	 CD	B-NP
,  	,  	 ,	O
open-label 	open-label 	 NNP	B-NP
,  	,  	 ,	O
repeat-dose  	repeat-dose  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
( 	( 	 -LRB-	O
one  	one  	 CD	O
of  	of  	 IN	O
which  	which  	 WDT	O
was  	was  	 VBD	O
an  	an  	 DT	O
extension  	extension  	 NN	B-NP
trial 	trial 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Two  	Two  	 CD	O
fixed-dose 	fixed-dose 	 NN	B-NP
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
studies  	studies  	 NNS	O
randomized  	randomized  	 VBP	O
a  	a  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
416  	416  	 CD	O
patients  	patients  	 NNS	O
to  	to  	 TO	O
receive  	receive  	 VB	O
one  	one  	 CD	O
50-unit  	50-unit  	 CD	O
dose  	dose  	 NN	O
of  	of  	 IN	O
BoNTA-ABO 	BoNTA-ABO 	 JJ	B-NP
.  	.  	 .	O
The  	The  	 DT	O
single  	single  	 JJ	O
variable-dose  	variable-dose  	 JJ	B-NP
study  	study  	 NN	I-NP
randomized  	randomized  	 VBD	O
544  	544  	 CD	O
patients  	patients  	 NNS	O
to  	to  	 TO	O
receive  	receive  	 VB	O
50  	50  	 CD	O
to  	to  	 TO	O
80  	80  	 CD	O
units  	units  	 NNS	O
of  	of  	 IN	O
BoNTA-ABO 	BoNTA-ABO 	 NNP	B-NP
,  	,  	 ,	O
as  	as  	 RB	O
determined  	determined  	 VBN	O
by  	by  	 IN	O
gender  	gender  	 NN	B-NP
and  	and  	 CC	O
patient  	patient  	 JJ	O
muscle  	muscle  	 NN	B-NP
mass 	mass 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
substudy  	substudy  	 NN	B-NP
of  	of  	 IN	O
this  	this  	 DT	O
variable-dose  	variable-dose  	 JJ	B-NP
study  	study  	 NN	I-NP
on  	on  	 IN	O
QT 	QT 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
QTc  	QTc  	 JJ	I-NP
prolongation  	prolongation  	 NN	I-NP
included  	included  	 VBD	O
50  	50  	 CD	O
patients  	patients  	 NNS	O
randomized  	randomized  	 VBP	O
to  	to  	 TO	O
BoNTA-ABO 	BoNTA-ABO 	 JJ	B-NP
.  	.  	 .	O
One  	One  	 CD	O
open-label  	open-label  	 JJ	B-NP
repeat-dose  	repeat-dose  	 JJ	I-NP
study  	study  	 NN	I-NP
administered  	administered  	 VBN	O
50  	50  	 CD	O
units  	units  	 NNS	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
to  	to  	 TO	O
1200  	1200  	 CD	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
single  	single  	 JJ	O
extension  	extension  	 NN	B-NP
study  	study  	 NN	I-NP
( 	( 	 -LRB-	O
N  	N  	 NNP	O
=  	=  	 SYM	O
1415 	1415 	 CD	O
)  	)  	 -RRB-	O
included  	included  	 VBD	O
both  	both  	 DT	O
fixed  	fixed  	 JJ	O
( 	( 	 -LRB-	O
5423  	5423  	 CD	O
treatments 	treatments 	 NNS	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
variable  	variable  	 JJ	O
dosing  	dosing  	 NNS	O
( 	( 	 -LRB-	O
1337  	1337  	 CD	O
treatments 	treatments 	 NNS	O
)  	)  	 -RRB-	O
following  	following  	 VBG	O
a  	a  	 DT	O
protocol  	protocol  	 NN	B-NP
amendment 	amendment 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
extension  	extension  	 NN	B-NP
study  	study  	 NN	I-NP
included  	included  	 VBD	O
patients  	patients  	 NNS	O
from  	from  	 IN	O
the  	the  	 DT	O
four  	four  	 CD	O
previously  	previously  	 RB	O
mentioned  	mentioned  	 VBN	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
Safety  	Safety  	 NN	B-NP
endpoints  	endpoints  	 NNS	I-NP
were  	were  	 VBD	O
adverse  	adverse  	 JJ	B-NP
events  	events  	 NNS	I-NP
( 	( 	 -LRB-	O
AE 	AE 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
laboratory  	laboratory  	 NN	O
data 	data 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
changes  	changes  	 NNS	O
in  	in  	 IN	O
vital  	vital  	 JJ	O
signs 	signs 	 NNS	O
.  	.  	 .	O
Of  	Of  	 IN	O
2485  	2485  	 CD	O
healthy  	healthy  	 JJ	O
adult  	adult  	 NN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
moderate  	moderate  	 JJ	O
to  	to  	 TO	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
enrolled  	enrolled  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
trials 	trials 	 NNS	O
,  	,  	 ,	O
2160  	2160  	 CD	O
received  	received  	 VBN	O
at  	at  	 IN	O
least  	least  	 JJS	O
one  	one  	 CD	O
cycle  	cycle  	 NN	B-NP
of  	of  	 IN	I-NP
BoNTA-ABO 	BoNTA-ABO 	 JJ	I-NP
.  	.  	 .	O
Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
with  	with  	 IN	O
50  	50  	 CD	O
units  	units  	 NNS	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
was  	was  	 VBD	O
well  	well  	 RB	O
tolerated 	tolerated 	 JJ	O
,  	,  	 ,	O
with  	with  	 IN	O
similar  	similar  	 JJ	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
treatment-emergent  	treatment-emergent  	 JJ	B-NP
adverse  	adverse  	 JJ	I-NP
events  	events  	 NNS	I-NP
( 	( 	 -LRB-	O
TEAE 	TEAE 	 NNP	B-NP
)  	)  	 -RRB-	O
observed  	observed  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
active  	active  	 JJ	O
treatment  	treatment  	 NN	O
and  	and  	 CC	O
placebo  	placebo  	 JJ	O
groups  	groups  	 NNS	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
type 	type 	 NN	O
,  	,  	 ,	O
frequency 	frequency 	 NN	O
,  	,  	 ,	O
severity 	severity 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
relatedness-with  	relatedness-with  	 JJ	B-NP
the  	the  	 DT	O
exception  	exception  	 NN	O
of  	of  	 IN	O
injection  	injection  	 NN	B-NP
site  	site  	 NN	I-NP
reactions  	reactions  	 NNS	I-NP
and  	and  	 CC	O
ptosis 	ptosis 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
variable-dose 	variable-dose 	 JJ	B-NP
,  	,  	 ,	O
single-treatment  	single-treatment  	 JJ	B-NP
study 	study 	 NN	I-NP
,  	,  	 ,	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
was  	was  	 VBD	O
well  	well  	 RB	O
tolerated 	tolerated 	 JJ	O
,  	,  	 ,	O
with  	with  	 IN	O
an  	an  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
active  	active  	 JJ	O
TEAE  	TEAE  	 NNP	B-NP
( 	( 	 -LRB-	O
31 	31 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
only  	only  	 RB	O
slightly  	slightly  	 RB	O
greater  	greater  	 JJR	O
than  	than  	 IN	O
that  	that  	 WDT	O
observed  	observed  	 VBD	O
for  	for  	 IN	O
placebo  	placebo  	 NNS	O
( 	( 	 -LRB-	O
28 	28 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
repeat-dose  	repeat-dose  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
,  	,  	 ,	O
there  	there  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
cumulative  	cumulative  	 JJ	B-NP
safety  	safety  	 NN	I-NP
issues 	issues 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
TEAE  	TEAE  	 NNP	B-NP
decreased  	decreased  	 VBD	O
over  	over  	 IN	O
time 	time 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
patients  	patients  	 NNS	O
did  	did  	 VBD	O
not  	not  	 RB	O
drop  	drop  	 VB	O
out  	out  	 RP	O
because  	because  	 IN	O
of  	of  	 IN	O
TEAE 	TEAE 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
frequently  	frequently  	 RB	O
reported  	reported  	 VBD	B-NP
AE  	AE  	 NNP	I-NP
were  	were  	 VBD	O
nasopharyngitis 	nasopharyngitis 	 CD	B-NP
,  	,  	 ,	O
sinusitis 	sinusitis 	 NN	O
,  	,  	 ,	O
upper  	upper  	 JJ	O
respiratory  	respiratory  	 JJ	B-NP
tract  	tract  	 NN	I-NP
infection 	infection 	 NN	I-NP
,  	,  	 ,	O
headache 	headache 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
injection  	injection  	 NN	B-NP
site  	site  	 NN	I-NP
reactions 	reactions 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
majority  	majority  	 NN	O
of  	of  	 IN	O
TEAE  	TEAE  	 NNP	B-NP
were  	were  	 VBD	O
considered  	considered  	 VBN	O
unlikely  	unlikely  	 JJ	O
to  	to  	 TO	O
be  	be  	 VB	O
related  	related  	 VBN	O
or  	or  	 CC	O
were  	were  	 VBD	O
not  	not  	 RB	O
related  	related  	 VBN	O
to  	to  	 TO	O
BoNTA-ABO  	BoNTA-ABO  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
all  	all  	 DT	O
studies 	studies 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
TEAE  	TEAE  	 NN	B-NP
that  	that  	 WDT	O
were  	were  	 VBD	O
considered  	considered  	 VBN	O
possibly  	possibly  	 RB	O
related  	related  	 VBN	O
to  	to  	 TO	O
treatment  	treatment  	 NN	O
were  	were  	 VBD	O
primarily  	primarily  	 RB	O
headaches  	headaches  	 NNS	O
( 	( 	 -LRB-	O
with  	with  	 IN	O
rates  	rates  	 NNS	O
comparable  	comparable  	 JJ	O
to  	to  	 TO	O
those  	those  	 DT	O
observed  	observed  	 NN	O
for  	for  	 IN	O
placebo 	placebo 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
injection  	injection  	 NN	B-NP
site  	site  	 NN	I-NP
reactions 	reactions 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
eye  	eye  	 NN	B-NP
disorders  	disorders  	 NNS	I-NP
( 	( 	 -LRB-	O
such  	such  	 JJ	O
as  	as  	 IN	O
blepharospasm  	blepharospasm  	 NN	B-NP
and  	and  	 CC	O
eyelid  	eyelid  	 JJ	B-NP
ptosis 	ptosis 	 NN	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
clinically  	clinically  	 JJ	O
significant  	significant  	 JJ	O
changes  	changes  	 NNS	O
in  	in  	 IN	O
hematologic  	hematologic  	 NN	B-NP
or  	or  	 CC	O
biochemical  	biochemical  	 JJ	B-NP
parameters  	parameters  	 NNS	I-NP
or  	or  	 CC	O
in  	in  	 IN	O
vital  	vital  	 JJ	O
signs 	signs 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
cardiovascular  	cardiovascular  	 JJ	B-NP
substudy  	substudy  	 NN	I-NP
revealed  	revealed  	 VBD	O
that  	that  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
had  	had  	 VBD	O
no  	no  	 DT	O
effect  	effect  	 NN	O
on  	on  	 IN	O
QT 	QT 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
QTc  	QTc  	 JJ	I-NP
prolongation 	prolongation 	 NN	I-NP
.  	.  	 .	O
Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
with  	with  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
is  	is  	 VBZ	O
well  	well  	 RB	O
tolerated 	tolerated 	 VBN	O
.  	.  	 .	O
Overall 	Overall 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
safety  	safety  	 NN	O
profile  	profile  	 NN	O
of  	of  	 IN	O
BoNTA-ABO  	BoNTA-ABO  	 NNP	B-NP
is  	is  	 VBZ	O
comparable  	comparable  	 JJ	O
to  	to  	 TO	O
that  	that  	 DT	O
of  	of  	 IN	O
placebo  	placebo  	 NN	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
type 	type 	 NN	O
,  	,  	 ,	O
frequency 	frequency 	 NN	O
,  	,  	 ,	O
severity 	severity 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
relatedness  	relatedness  	 NN	B-NP
of  	of  	 IN	I-NP
AE 	AE 	 NNP	I-NP
.  	.  	 .	O
